SSRIs vs. Psychedelics: Why One Blunts and the Other Reboots

Most practitioners working in psychedelics eventually field the same question, usually from a client who has been on an antidepressant for years: how is this different from what I’m already taking? The honest answer has less to do with which one works better and more to do with what each one does. SSRIs and psychedelics both act on serotonin, but at the level of brain activity and the emotional processing that rides on it, they appear to be doing close to opposite things.

Much of what we know about that difference comes from the neuroimaging work of Robin Carhart-Harris, Ph.D., a Psychedelic Coaching Institute faculty member who ran the first psilocybin brain imaging study, the first modern psilocybin trial for treatment-resistant depression, and the head-to-head trial comparing psilocybin therapy against an SSRI. What follows is a walk through that research, with some notes on what is well supported and what is still unsettled.

What Patients Said Before the Scanners Did

The comparison between SSRIs and psychedelics did not begin as a study design. It began in interviews.

In a trial published in The Lancet Psychiatry in 2016, people with treatment-resistant depression received psilocybin therapy: one low dose, then one 25mg dose a week later. The first 12 participants were reported in that paper, with the full group of 20 published the following year. Every participant had already tried SSRIs. Some had tried as many as 14 different antidepressants. Nearly all had tried psychotherapy, and a few had tried electroconvulsive therapy or transcranial magnetic stimulation. Nothing had worked. After two doses of psilocybin, everyone showed some improvement within a week, with the largest effects at five weeks.

When researchers interviewed each participant afterward, the same themes kept surfacing: more acceptance of emotion, a stronger sense of connection to their bodies and to other people, a renewed sense of meaning. And, without being asked, patients kept comparing the experience to their SSRIs. The medication took the edge off, they said, which helped with harsh self-criticism. But it took the edge off joy too. They felt flattened. Several mentioned the sexual side effects.

Those unprompted comparisons were part of what motivated the head-to-head trial that followed.

How an SSRI Changes Brain Activity

Selective serotonin reuptake inhibitors raise the amount of serotonin circulating in the brain, slowly and broadly. Where that matters most for mood is a receptor called 5-HT1A, which is densely expressed in the brain’s stress circuitry. Stimulating those receptors dampens activity there, so the person becomes less reactive to stressful input. That is the buffering effect SSRIs are known for, and it is real.

The cost is that the dampening does not discriminate. Brain imaging of people six weeks into treatment with escitalopram (sold as Lexapro) shows a general blunting of responsiveness to emotional faces, and the blunting applies to fearful, happy, and neutral expressions alike. The system is quieter across the board. This may be the physiological signature behind what patients describe as feeling flattened.

Serotonin itself deserves a word of caution here. Of all the brain’s chemical messengers, it is probably the most complicated, involved in mood, sleep, consciousness, digestion, and basic bodily regulation. One researcher described it as involved in everything and responsible for nothing. That complexity is part of why “serotonin imbalance” was always too simple an explanation for depression, and why raising serotonin levels has such mixed results across people.

How a Psychedelic Changes Brain Activity

Classic psychedelics like psilocybin and LSD work through a different serotonin receptor, 5-HT2A, which is concentrated in the cortex, the outer layer of the brain that humans have far more of than any other species relative to body size. The regions with the most 5-HT2A receptors are the ones that handle associative, abstract thought.

Stimulating those receptors produces what Carhart-Harris calls the entropic brain effect: activity becomes more varied, less predictable, and less locked into its usual patterns. Brain networks that normally stay well separated start communicating with each other, and networks that normally fire in sync fall out of step.

The network most affected is the default mode network, a set of metabolically expensive cortical regions involved in imagining the future, recalling the past, and maintaining a sense of self. It is the brain’s storytelling machinery, and it is massively expanded in humans compared with other mammals. In the first psilocybin fMRI study, published in 2012, the default mode network showed reduced activity and, more notably, a loss of synchrony between its nodes. Regions that usually rise and fall together stopped doing so. That finding has since been replicated several times, including in a 2024 paper in Nature.

The contrast with SSRIs shows up clearly in the head-to-head data. People treated with psilocybin therapy still showed traces of this network reorganization three weeks after their second dose, and the size of that lingering effect tracked with how much their depression improved. The SSRI group showed no change on that measure. Escitalopram blunted emotional responsiveness; psilocybin therapy left that largely intact. The one difference it did produce was a slightly increased response to neutral faces, which reads less like suppression and more like a recalibration.

Carhart-Harris’s own shorthand for the distinction is that an SSRI works as a symptom management strategy, while psilocybin therapy looks more like a reboot to factory settings. It is an interpretation, but it fits the imaging.

The REBUS Model: Why a Reboot Might Help

The theory behind that reboot is called REBUS, short for relaxed beliefs under psychedelics. The idea is that in mental illness, certain beliefs become too strong and too hard to escape. They can be cognitive (I am worthless), emotional, or behavioral, as in the grooved habits of addiction. The term borrowed to describe this is canalization: a pattern carved so deep that thought and behavior keep falling back into it.

The default mode network is where much of that narration lives. When a psychedelic scrambles its activity, the carved channels may lose some of their pull, and the person gets a window in which a different story becomes possible. SSRIs, by this account, do not touch the channels at all. They lower the water level.

This is also why the psychological side of the experience may carry as much weight as the biology. In studies that measure psychological insight the day after a psychedelic session, the degree of insight predicts the degree of improvement in mental health. That appears to be a psychedelic-specific effect. It does not show up with placebo, and nothing in the SSRI data so far suggests it shows up there either. When people were asked to rate the core character of different compounds, psilocybin mushrooms scored highest on statements like “I could see deeply into the human mind.” Ketamine’s core effect was dissociation. MDMA’s was feelings of love. They can be grouped together as psychedelics, but they are not doing the same thing.

The Neuroplasticity Claim, With Its Caveats

Neuroplasticity is often presented as the settled mechanism behind psychedelic benefit. It is not settled, at least not in humans.

Nearly all of the direct evidence comes from rodents or from neurons in a dish. What that work shows, fairly consistently, is growth in the dendrites and dendritic spines of cortical neurons, the branch-like structures that receive incoming signals. It does not show growth of new neurons, which is a different claim that has not been demonstrated convincingly. One mouse study found spine growth from a single dose of psilocybin still present a month later.

SSRIs also appear to promote plasticity in animal work, but the effect is more modest and mostly confined to stress circuitry in the hippocampus. What stands out about psychedelics in these studies is the size of the effect from so few doses, which would fit the clinical picture of rapid and lasting change after one or two sessions.

In humans, the tools available are indirect. One preprint using diffusion tensor imaging found a measurable change in white matter tracts running from the prefrontal cortex into the thalamus one month after a person’s first ever high dose of psilocybin, with no change after placebo a month earlier. It is preliminary and has spent years in peer review. Whether it holds, and what it means, is still open.

For practitioners, the useful takeaway is restraint. Plasticity in its most basic sense just means changeability, and psychedelics clearly promote that. Whether the mechanism is anatomical, psychological, or both, a client who is no longer depressed is the outcome that matters, and it does not need a brain scan to be real.

What Happens When a Medicated Client Wants Psychedelic Work?

This is the part with the most direct consequences for practice, and the evidence is mixed.

In the head-to-head trial, roughly half the participants came in on an SSRI and tapered off before treatment. The other half arrived medication-free. Those who had tapered off did not respond as well to psilocybin therapy as those who were never medicated. One hypothesis is that long-term SSRI use desensitized their brains to the psychedelic. Another is psychological: the people who avoided SSRIs may have arrived more receptive to a different kind of treatment. Curiously, those who tapered off and were then randomized back onto escitalopram did better than the medication-free group on the same drug, which may say something about discontinuation effects, or about familiarity.

Two studies have reported that people can stay on their SSRI and still benefit from psilocybin. One, an open-label trial from Compass Pathways, gave psilocybin to depressed patients who remained on their antidepressant. The other, from Matthias Liechti’s lab at University Hospital Basel, found that two weeks of escitalopram pretreatment did not blunt psilocybin’s positive mood effects in healthy volunteers. Its authors noted the obvious limitation: two weeks may be too short to reproduce the receptor changes that build up over years of use.

Not everyone is convinced. Carhart-Harris has said he is skeptical and has pointed out the commercial reason a company might want that finding to be true: a treatment that requires no taper has a far larger pool of eligible patients. His view is that clients likely benefit most if they discontinue first, provided the withdrawal period is managed well. Symptoms of depression and anxiety often get worse for a stretch when someone comes off an SSRI, which is exactly the window where skilled support matters.

There is also a safety dimension. Because SSRIs keep more serotonin active in the system and classic psychedelics stimulate serotonin receptors, combining them carries a risk of serotonin syndrome. It is uncommon, but it is medically serious, and the risk appears to rise with dose.

Ketamine sits outside this problem. It produces a version of the same entropic scramble, but through glutamate, the brain’s main excitatory neurotransmitter, rather than serotonin. It does not compete with an SSRI, which is why ketamine therapy is commonly given to people still on antidepressants and why some psychiatrists use it as a bridge during the taper.

Where Microdosing Fits

Estimates suggest several million Americans microdosed psilocybin in 2023, and the research has not kept pace. The reason is mostly logistical. Getting an ethics board to approve sending people home with a Schedule I drug is nearly impossible, so a rigorous microdosing trial means a lab visit for every dose across several weeks. That is expensive, and it is why the literature is thin.

What exists is suggestive. An fMRI study with 13 micrograms of LSD found brain changes resembling what is seen at full doses, at a lower intensity. An EEG study across three low doses found the entropy of brain activity rose with each step up in dose. The same study found no such effect with cannabis or with methylphenidate. The working interpretation is that a microdose may be the same essential thing as a macrodose, diluted. Whether that dilution is enough to produce a reliable therapeutic effect is the question no one has properly tested yet.

Summary: Two Tools, Two Mechanisms

An SSRI narrows the range of what a person feels so that stress lands more softly. A psychedelic loosens the brain’s entrenched patterns so that a different way of feeling and thinking becomes available. Both can be the right tool, and the ideal practitioner toolkit has room for each. But they are not interchangeable, and a client moving from one toward the other is crossing a physiological line that deserves to be treated as one.

The practitioners who serve these clients well understand the mechanism on both sides of that line, and understand that the transition between them is where most of the risk lives.

That transition is the entire subject of the SSRI Deprescribing & Psychedelic Readiness certification at the Psychedelic Coaching Institute. David Rabin, M.D., Ph.D. teaches the full protocol across six live sessions, from readiness assessment through the taper to the nervous system support that keeps clients off, with Robin Carhart-Harris joining as guest faculty. If the science above is the kind of thing you want to work with rather than just read about, that program is built for you. [Link]